Fact-checked by Grok 2 weeks ago

NJOY


NJOY, LLC is an manufacturer of cigarettes and vaping products, specializing in pod-based systems and disposable devices as alternatives to combustible tobacco cigarettes. Founded in 2007 in , the company pioneered early e-cigarette innovations, including the disposable "King" model launched in 2012, and grew to become one of the leading independent producers of nicotine delivery systems (ENDS) in the United States. Acquired by Group in a $2.75 billion transaction completed in 2023, NJOY now operates as a wholly owned , integrating its portfolio—highlighted by the NJOY pod device and NJOY Daily disposables—into Altria's broader reduced-risk product strategy.
The company's products, available in tobacco and menthol flavors at nicotine strengths such as 4.5% and 6% by weight, have received marketing granted orders from the U.S. (FDA) following rigorous premarket tobacco product application (PMTA) reviews, which determined that the benefits of aiding adult smokers in switching from cigarettes outweigh potential risks when marketed with appropriate restrictions. NJOY's regulatory milestones include FDA authorizations in 2022 for certain -flavored variants and in 2024 for menthol options, based on demonstrating reduced harm relative to and limited appeal to non-smokers. Defining characteristics encompass a focus on closed-system devices to minimize youth access and a history of legal challenges against FDA delays in flavored product reviews, including a 2025 lawsuit alleging violations of statutory deadlines under the Family Prevention and Tobacco Control Act. These efforts reflect NJOY's emphasis on empirical data supporting ENDS as a tool amid ongoing debates over vaping's impacts.

Founding and Early History

Inception and Initial Operations (2006–2010)

NJOY was established in 2006 by Arizona attorney Mark Weiss and his brothers Craig and Jeffrey Weiss in Scottsdale, Arizona, initially operating as Sottera, Inc., doing business as NJOY. The founding stemmed from Mark Weiss encountering rudimentary electronic cigarette prototypes, prompting the family to import and commercialize battery-powered nicotine vaporizers as alternatives for adult smokers. Early operations centered on a modest setup with approximately 10 employees in Scottsdale Airpark offices, emphasizing importation of e-cigarettes—primarily from manufacturers—and domestic distribution without advancing unverified health benefit assertions to avoid regulatory scrutiny. NJOY positioned itself among the pioneering U.S. e-cigarette brands, importing and selling rechargeable and disposable devices containing derived from plants, marketed through direct sales and emerging retail channels. Regulatory pressures emerged swiftly, as the FDA in 2009 sought to detain NJOY imports and classify e-cigarettes as unapproved drug-device combinations requiring premarket authorization. Sottera, Inc. (d/b/a ) intervened in related litigation, arguing against drug regulation; in December 2010, the U.S. Court of Appeals for the D.C. Circuit ruled that the FDA lacked authority to regulate e-cigarettes as drugs absent therapeutic claims, affirming their status as tobacco products under existing law and permitting NJOY's continued market presence. This decision marked a pivotal early validation of NJOY's operational model amid nascent industry uncertainties.

Expansion and Product Innovation (2011–2015)

In April 2012, NJOY received a $20 million from , a , which funded accelerated product development and distribution expansion amid rising demand for electronic cigarettes. This capital infusion supported the company's shift from niche online and kiosk sales to broader retail penetration, including partnerships with chains like , which began stocking NJOY products across nearly 600 locations by December. A pivotal innovation came in late 2012 with the launch of NJOY , a disposable engineered to replicate the physical experience of a traditional king-size , including comparable size, weight, draw resistance, and a soft, squeezable filter tip. Priced at $7.99 per pack and featuring a proprietary "master blend" flavor, the Kings emphasized high delivery without , positioning NJOY as an innovator in user satisfaction for alternatives. The product debuted nationally in December across over 30,000 convenience stores, marking NJOY's aggressive push into mass-market retail channels. Building on this momentum, NJOY released the 2.0 in late , an iterative upgrade incorporating refinements to battery life and vapor consistency to address user feedback on earlier disposables. By early 2014, the company diversified beyond disposables with promotions such as buy-one-get-one-free offers on to drive trial in and other mainstream outlets, where e-cigarette availability had surged. In May 2014, NJOY announced a refreshed lineup, introducing rechargeable electronic cigarettes for repeated use and high-vapor devices targeting emerging vaping enthusiasts seeking customizable experiences over cigarette . These moves reflected NJOY's adaptation to evolving preferences, with unit driven partly by larger pack sizes and flavored variants entering the market. Through 2015, NJOY's retail footprint continued expanding into traditional U.S. channels, with e-cigarette sales in these outlets reflecting broader industry trends of increased availability and promotional activity. The company's focus on disposable innovations like Kings solidified its position as a market leader in closed-system devices, though the introduction of rechargeables signaled preparation for competition from open-system vaping products. This period's developments underscored NJOY's strategy of balancing cigarette-like familiarity with incremental technological enhancements to capture share in a rapidly commercializing sector.

Product Portfolio

Core Devices and Systems

The NJOY ACE represents the company's flagship pod-based vaping system, consisting of a reusable battery device paired with pre-filled, disposable pods. Authorized by the U.S. (FDA) for marketing on January 15, 2020, for the device and select pods, with subsequent authorizations for additional variants including flavors on June 21, 2024, the system delivers via aerosolized e-liquid heated by a in the pod. The compact device measures 3.5 inches by 1.1 inches by 0.5 inches and weighs 2.2 ounces, featuring a 400 mAh rechargeable that sustains up to 24–36 hours of typical use per charge, with magnetic pod attachment for draw-activated operation without buttons. Pods hold 1.9 mL of e-liquid, providing approximately 325 puffs—comparable to one pack of cigarettes—and are available in strengths of 2.4% or 5.0% by weight. The NJOY Daily comprises disposable e-cigarette units, functioning as a single-use cigalike system without rechargeable components or replaceable parts. FDA marketing orders were issued for variants including tobacco and menthol flavors, with the menthol 4.5% product authorized on June 21, 2024, following earlier decisions for tobacco-flavored models on June 10, 2022. Activation occurs via inhalation, producing vapor from a fixed e-liquid reservoir without user-configurable settings, emphasizing simplicity for transitioning smokers. Each unit delivers a consistent nicotine dose until depletion, typically equivalent to one pack of cigarettes, though exact reservoir volume is not publicly specified in authorizations. Both systems employ closed architectures with pre-filled cartridges to restrict liquid access and reduce variability in composition, aligning with FDA premarket product application requirements demonstrating lower profiles relative to combustible cigarettes in authorized configurations. The offers reusability for cost efficiency over multiple pods, while the Daily prioritizes disposability for convenience without maintenance.
FeatureNJOY ACENJOY Daily
TypeRechargeable pod systemDisposable cigalike
Battery400 mAh lithium-ion, ~24–36 hoursNone (fixed internal power)
Cartridge1.9 mL pre-filled pods, magneticFixed reservoir, non-replaceable
Nicotine Strengths2.4%, 5.0% (select pods)4.5% (authorized menthol)
Puffs per Unit~325 per pod~Equivalent to 1 cigarette pack
FDA AuthorizationDevice & pods (2020+ updates)Specific flavors (2022+)

Flavors, Nicotine Options, and Formulations

NJOY's authorized e-cigarette products feature a restricted range of flavors, consisting exclusively of and variants, as approved by the U.S. (FDA). These include Classic , Rich , and , reflecting regulatory emphasis on reduced-risk profiles for smokers transitioning from combustible cigarettes rather than appealing to . Earlier NJOY offerings included additional flavors like or profiles, but post-FDA marketing granted orders issued between 2022 and 2024, only and remain legally marketable in the U.S. Nicotine concentrations in NJOY pods and disposables range from 2.4% to 6% by weight, tailored to different devices and user preferences. The NJOY ACE pod system offers 2.4% and 5% options for both and pods, while the disposable NJOY DAILY and DAILY EXTRA models provide 4.5% and 6% strengths, respectively. These levels are formulated to deliver comparable to traditional cigarettes, with FDA evaluations confirming appropriate delivery for without excessive appeal to non-users.
Product LineFlavorNicotine Strength (% by weight)
NJOY ACE POD2.4%, 5%
NJOY ACE POD5%
NJOY ACE POD2.4%, 5%
NJOY DAILY4.5%
NJOY DAILY4.5%
NJOY DAILY EXTRA6%
NJOY DAILY EXTRA6%
E-liquid formulations in NJOY products primarily comprise (PG) and vegetable glycerin (VG) as base solvents, with added , flavorings, and minor ingredients for stability and taste. These components enable generation upon heating, with PG contributing to throat hit and flavor carrier properties, while VG enhances vapor production. Specific PG/VG ratios and versus forms are not publicly detailed by NJOY for authorized products, though FDA-reviewed submissions indicate optimized compositions for consistent nicotine delivery and reduced irritancy compared to earlier iterations. Independent analyses of select NJOY e-liquids have identified 50:50 PG/VG blends in some disposables, supporting smoother at higher strengths.

Recent Product Launches

In June 2024, the U.S. (FDA) issued marketing granted orders authorizing NJOY to commercialize four menthol-flavored electronic nicotine delivery system products, marking the first such approvals for non-tobacco flavored e-vapor items. These included NJOY Pod Menthol 2.4% and 5.0% for use with the rechargeable NJOY device, as well as NJOY DAILY Menthol 4.5% and NJOY DAILY EXTRA Menthol 6.0% disposables. The authorizations followed extensive scientific review under the Family Smoking Prevention and Tobacco Control Act, determining that the products could be marketed with appropriate restrictions to protect . The NJOY DAILY line, initially authorized in tobacco flavors in June 2022 as the first FDA-approved disposable e-cigarette, expanded with these menthol variants to offer single-use options delivering 4.5% or 6.0% nicotine by weight in a compact, non-rechargeable format designed for adult smokers seeking alternatives to traditional cigarettes. Similarly, the menthol pods for the NJOY ACE pod system provide 2.4% or 5.0% nicotine strengths, compatible with the device's rechargeable battery and magnetic pod attachment mechanism. These launches built on prior FDA approvals for NJOY's tobacco-flavored ACE products in 2022, emphasizing reduced-risk profiles for adult tobacco users amid ongoing regulatory scrutiny of flavored vaping items. In May 2024, NJOY submitted a supplemental Premarket Tobacco Product Application (PMTA) to the FDA for the NJOY ACE 2.0 device, incorporating Bluetooth-enabled access restriction technology to limit underage use through age-verification features. As of October 2025, this updated rechargeable pod system awaits FDA review and has not yet been authorized for market entry, though redesigned variants have faced import challenges from disputes with competitors. The original NJOY ACE device faced temporary U.S. market removal in April 2025 following an International Trade Commission ruling on , prompting contingency planning for alternatives.

Premarket Applications and FDA Interactions

NJOY LLC submitted premarket tobacco product applications (PMTAs) to the U.S. Food and Drug Administration (FDA) for its electronic nicotine delivery systems (ENDS), including the NJOY ACE pod system and NJOY DAILY disposables, prior to the September 9, 2020, deadline for products marketed before August 8, 2016, as required by the Family Smoking Prevention and Tobacco Control Act. In March 2020, the company filed PMTAs for eight variations of the NJOY DAILY line of disposable ENDS products. These submissions included scientific data on product characteristics, health risks, and behavioral studies to support assessments of whether marketing would be appropriate for the protection of public health (APPH). The FDA's PMTA review process encompasses acceptance review to confirm completeness, filing review for regulatory sufficiency, and substantive scientific evaluation, often extending beyond the statutory 180-day due to the volume of applications—over 26 million products covered by approximately 500,000 submissions. NJOY's applications advanced through these stages, with the company responding to FDA requests for additional information; in March 2021, NJOY provided details on survey methodologies and six-month longitudinal outcome data from user perception and behavioral studies for its DAILY products. This interaction addressed potential deficiencies identified during filing and early substantive reviews, enabling progression to full evaluation. Subsequent FDA decisions on NJOY's PMTAs included marketing granted orders for tobacco-flavored pods (Classic 2.4% and 5%, Rich 5%) and the ACE on April 26, 2022, marking the first authorizations for a closed-pod ENDS system. Additional grants followed for NJOY DAILY EXTRA Rich 6% on June 10, 2022, and menthol-flavored ACE and DAILY variants (e.g., ACE Pod 2.4% and 5%) on June 21, 2024, after extensive review of abuse liability and youth appeal data. In May 2024, NJOY filed a supplemental PMTA for the NJOY ACE 2.0 , incorporating Bluetooth-enabled age-verification and access-restriction features to mitigate youth access risks. Perceived delays in FDA reviews for certain flavored products prompted legal challenges; in 2025, Group Inc., which acquired NJOY in 2023, sued the FDA over protracted internal deliberations on NJOY DAILY flavored ENDS marketing denial orders, arguing unreasonable postponement of substantive decisions post-filing. These interactions highlight ongoing tensions in the PMTA pathway, where FDA scrutiny emphasizes long-term health impacts and reduced-risk claims amid high application volumes.

Key Authorizations and Denials

In April 2022, the U.S. Food and Drug Administration (FDA) issued marketing granted orders (MGOs) for the NJOY ACE pod-based electronic nicotine delivery system (ENDS), including the NJOY ACE device and three tobacco-flavored pods: Classic Tobacco 2.4%, Classic Tobacco 5%, and Rich Tobacco 5%. These authorizations marked NJOY as one of the first companies to receive FDA approval for a closed-pod system, following a review of premarket tobacco product applications (PMTAs) submitted in 2017, with the FDA determining that the products were appropriate for the protection of public health based on evidence of potential benefits for adult smokers switching from combustible cigarettes. The FDA simultaneously issued marketing denial orders (MDOs) for several other NJOY products, including non-tobacco flavored pods such as Cool Mint and Tropical Breeze, citing insufficient evidence that the net benefits—primarily from adult smokers' potential switching—outweighed the risks of initiation and appeal due to flavors. NJOY later appealed some of these denials, but as of October 2025, flavored variants remain unauthorized pending resolution. In June 2022, the FDA granted MGOs for two NJOY DAILY disposable ENDS products: DAILY EXTRA Rich Tobacco 4.5% and 6% nicotine strengths, again deeming them appropriate for protection after evaluating PMTAs that included behavioral and epidemiological data on switching and . However, the agency issued MDOs for multiple flavored NJOY DAILY variants, including Blue + Black Berry, Watermelon, and others, determining that the flavors posed undue youth risk without adequate offsetting adult benefits. NJOY appealed these flavored denials in 2022, but the FDA's internal review of the MDOs has extended beyond statutory deadlines under the Tobacco Control Act, prompting a in August 2025 alleging unreasonable delay. On June 21, 2024, the FDA authorized four -flavored NJOY products—the NJOY Pod 2.4%, NJOY Pod 5%, and associated device components—representing the first non-tobacco flavored ENDS to receive MGOs, based on supplemental PMTA evidence demonstrating lower appeal compared to sweeter flavors and potential switching benefits. This decision followed extensive scientific review, including post-market data from prior tobacco authorizations, though it drew criticism from groups concerned about menthol's established appeal to and certain demographics. NJOY submitted further PMTAs in May 2024 for the NJOY 2.0 device with Bluetooth-enabled age verification, but outcomes remain pending as of October 2025.

Ongoing Litigation and Challenges

In August 2025, NJOY, LLC, a subsidiary of Group, Inc., along with three Louisiana-based tobacco retailers, filed a federal lawsuit against the U.S. (FDA) in the U.S. District Court for the Western . The challenges the FDA's three-year delay in resolving NJOY's supervisory appeal of a marketing denial order (MDO) for flavored disposable nicotine delivery systems (ENDS), alleging violations of the Family Prevention and Tobacco Control Act's statutory deadlines for agency action. NJOY contends that the FDA's inaction constitutes arbitrary and capricious conduct under the , seeking a to compel a decision and potentially monetary relief for lost market opportunities. As of October 2025, the case remains pending, highlighting broader industry frustrations with FDA review timelines amid ongoing debates over flavored products' youth appeal versus adult smoker switching potential. NJOY has faced significant challenges from Labs, Inc., escalating into multiple international proceedings. In August 2025, filed additional complaints with the U.S. International Trade Commission () and the U.S. District Court for the District of , accusing NJOY and of infringing patents related to pod-based vaping technology in products like the NJOY and Daily systems. The 's January 2025 ruling found that certain NJOY imports violated 's patents, prompting a limited exclusion order that halted U.S. imports and sales of affected Ace variants effective March 31, 2025. responded by voluntarily withdrawing the NJOY from the U.S. market to comply, while NJOY has pursued appeals and counteractions, including revocation challenges in the in Europe, where a November 2024 Paris division ruling upheld a key against NJOY's claims. These disputes, ongoing as of late 2025, underscore competitive tensions in the pod vaping segment and potential disruptions to NJOY's authorized product lines. To combat unregulated competition, NJOY initiated broad litigation in October 2023 against 34 foreign and domestic entities, including manufacturers like iMiracle HK Ltd. (Elf Bar), for producing and distributing flavored disposable vapes that allegedly evade 's flavor ban and federal premarket requirements. Claims under 's Unfair assert that these illicit products undermine compliant manufacturers by avoiding costly FDA premarket tobacco product applications (PMTAs) and state restrictions, distorting competition. A October 2025 ruling in the NJOY vs. Elf Bar case affirmed that noncompliant disposables provide unfair advantages, granting partial injunctions but leaving enforcement and damages unresolved. Several cases persist in U.S. district courts, with NJOY securing preliminary wins against unauthorized sellers, though challenges include jurisdictional issues with overseas defendants and the proliferation of copycat brands. These efforts reflect NJOY's strategy to enforce amid a flooded with non-FDA-authorized alternatives.

Acquisition and Corporate Evolution

Altria Acquisition (2023)

On March 6, 2023, Group, Inc. announced a definitive agreement to acquire NJOY Holdings, Inc. for approximately $2.75 billion in cash, granting full ownership of NJOY's global e-vapor portfolio, including the NJOY ACE pod-based system. The deal included potential additional payments of up to $500 million contingent on favorable regulatory outcomes for certain NJOY products pending review by the U.S. Food and Drug Administration (FDA). The acquisition received antitrust clearance when the Hart-Scott-Rodino waiting period expired on May 26, 2023, paving the way for completion without further regulatory hurdles from U.S. authorities. Altria funded the $2.75 billion purchase through existing cash reserves and emphasized the strategic fit, citing NJOY's FDA marketing authorizations for tobacco- and menthol-flavored products as a foundation for expanding reduced-risk alternatives to adult smokers. The transaction closed on June 1, , integrating NJOY's operations under and enabling accelerated national distribution of authorized NJOY e-vapor products through Altria's established channels. Post-closing, Altria reaffirmed its adjusted guidance, incorporating NJOY's contributions while committing to responsible focused on adult smokers and vapers transitioning from combustible cigarettes.

Post-Acquisition Integration and Strategy

Upon completion of the acquisition on June 1, 2023, NJOY Holdings, Inc. became a wholly owned subsidiary of Altria Group, Inc., enabling immediate access to Altria's established infrastructure for e-vapor commercialization. Altria appointed Sumedha Mohan, previously NJOY's chief commercial officer, as the new president and CEO of NJOY, signaling a continuity in operational leadership while integrating under Altria's oversight. Integration emphasized rapid execution of NJOY's preexisting business plans, including accelerated rollout of FDA-authorized products like the NJOY ACE pod system through Altria's vast retail distribution network, which spans over 225,000 U.S. stores. This leveraged Altria's sales expertise to enhance product availability and trial among adult smokers, aligning with Altria's broader vision of transitioning consumers to smoke-free nicotine alternatives. Strategically, Altria prioritized marketing investments to boost awareness and conversion rates for NJOY's authorized e-vapor offerings, focusing on and flavors compliant with FDA standards to appeal to current smokers without targeting . The approach aimed to capture share in the closed-pod e-vapor segment, where NJOY held the only fully authorized pod-based system as of mid-, positioning it to offset declining combustible volumes. By leveraging synergies in and consumer insights, Altria sought to scale NJOY's operations while pursuing regulatory advancements, including premarket product applications (PMTAs) for expanded formulations. In 2024, integration yielded tangible results, with NJOY shipment volumes growing significantly—contributing to a 15% increase in certain periods—and gaining in e-vapor, helping stabilize 's overall portfolio amid a 7.5% drop in smokeable products. However, full financial accretion remained pending, with projections for positive impact on in 2025 and adjusted diluted in 2026, contingent on sustained volume growth and regulatory progress. Ongoing efforts include litigation to expedite FDA reviews of flavored pod applications, as NJOY filed suit in August 2025 alleging unreasonable delays in marketing denial order processes for non-tobacco flavors, underscoring a push for portfolio diversification within legal bounds. Challenges such as disputes, including Labs' August 2025 infringement claims against NJOY and over pod technology, have introduced hurdles to seamless expansion.

Leadership and Personnel

Founders and Early Key Figures

NJOY was founded in 2006 by Mark H. Weiss, an attorney practicing in . Weiss, who had previously worked in patent law, established the company—initially incorporated as Sottera, Inc.—after a business trip to exposed him to rudimentary electronic cigarettes, prompting him to pursue their commercialization as a reduced-risk alternative to traditional smoking in the United States. Weiss's brothers, Craig Weiss and , served as co-founders and contributed significantly to the company's formative years. Craig Weiss, a fellow and former manager, focused on , strategy, and operational leadership, eventually assuming the role of CEO after NJOY's 2016 bankruptcy restructuring. supported early business development and strategic decisions alongside the founding team. The brothers' legal expertise proved instrumental in navigating initial regulatory hurdles, including NJOY's successful 2010 federal court challenge against the FDA's classification of e-cigarettes as unapproved drugs, which affirmed their status as products. Early operations were modest, with the initial office in Scottsdale accommodating about 10 employees and emphasizing rechargeable devices like the NJOY King, launched as a disposable option to mimic traditional experience. This core group's emphasis on and market positioning helped NJOY emerge as one of the first major independent e-cigarette brands in the U.S., prior to broader industry consolidation.

Current Executive Team

Shannon Leistra serves as President and Chief Executive Officer of NJOY, a position she assumed on June 1, 2023, immediately following Group, Inc.'s completion of its $2.75 billion acquisition of the company. Prior to this role, Leistra held the position of Senior Vice President and Consumer Experience Officer at Client Services LLC, bringing extensive experience in general management, M&A integration, marketing, and consumer strategy to NJOY's operations, which are now based in . Key supporting executives include Paige Magness, Senior Vice President of , who has represented NJOY in public statements on FDA matters, such as the agency's authorization of NJOY's e-vapor products on June 21, 2024. Jason J. Rosen continues as Executive Vice President of Policy and , overseeing interactions with regulatory bodies amid ongoing FDA scrutiny of e-vapor products. holds the role of Chief Engagement Officer and Deputy General Counsel, contributing to legal and stakeholder engagement efforts post-acquisition. The executive structure reflects NJOY's integration as a wholly-owned subsidiary of , with leadership focused on , product innovation, and market expansion for FDA-authorized devices like NJOY ACE and NJOY DAILY. Pre-acquisition figures such as Ryan Nivakoff, who served as CEO prior to the deal, transitioned out following the ownership change.

Scientific and Public Health Context

Evidence on Vaping as Aid

A 2024 Cochrane systematic review of randomized controlled trials (RCTs) concluded that nicotine electronic cigarettes (ECs) increase biochemically verified quit rates compared to nicotine replacement therapy (NRT), with high-certainty evidence showing a relative risk (RR) of 1.59 (95% CI 1.30 to 1.93) for abstinence at six months or longer. The review analyzed data from multiple trials involving over 13,000 participants, finding that for every 100 smokers using nicotine ECs, 8 to 10 achieve sustained abstinence, versus 6 per 100 using NRT. Moderate-certainty evidence indicated nicotine ECs outperform non-nicotine ECs or no aid, though long-term data beyond one year remain limited. A landmark 2019 multicenter RCT published in the New England Journal of Medicine randomized 886 smokers to either ECs or NRT (patches, gum, or lozenges) with behavioral support, yielding one-year abstinence rates of 17.7% for the EC group versus 8.0% for NRT ( 2.21; 95% 1.48 to 3.31). Participants using ECs reported higher satisfaction and adherence, contributing to superior outcomes, though the study noted potential for dual use during the quit attempt. A 2023 of eight RCTs corroborated this, finding ECs superior to NRT or behavioral alone in achieving abstinence ( 1.71; 95% 1.19 to 2.44), with no significant increase in serious adverse events. Further supporting evidence from a 2024 RCT in JAMA Internal Medicine compared ECs to and NRT among 810 Italian smokers, reporting six-month quit rates of 25.4% for ECs, 26.9% for , and 12.0% for , establishing ECs as comparably effective to the gold-standard . These findings align with causal mechanisms where ECs deliver more rapidly and controllably than NRT, mimicking smoking's sensory and pharmacokinetic profile to reduce and cravings. However, observational data sometimes show mixed results due to factors like self-selection among users, underscoring the primacy of RCT evidence over cohort studies for . While NJOY products, as authorized ECs, fall within this evidentiary framework, no large-scale RCTs specifically evaluating NJOY devices for cessation were identified in peer-reviewed literature as of 2025; general vaping applies, with tied to delivery rather than brand-specific hardware. Critics, often from advocacy, argue for caution due to initiation risks, but cessation trials consistently demonstrate net benefits for smokers when ECs replace combustible cigarettes. Overall, empirical data position vaping as a viable, -based cessation aid superior to traditional NRT for motivated smokers.

Criticisms and Risk Assessments

NJOY electronic cigarettes, like other nicotine delivery systems, expose users to , a highly addictive substance that can impair adolescent , increase , and elevate . Aerosols from NJOY devices contain potentially harmful chemicals, including , , and —byproducts of heating and vegetable glycerin—which have been linked to lung irritation, , and cardiovascular strain in laboratory and human studies. While toxin levels in NJOY products are substantially lower than in combustible cigarettes, prolonged exposure may still contribute to respiratory conditions such as chronic or exacerbations, based on evidence from e-cigarette users broadly. Long-term risks, including potential carcinogenicity, remain uncertain due to the relative novelty of pod-based systems like NJOY , with epidemiological data limited to short-term outcomes. Public health advocates have criticized NJOY's menthol-flavored products, authorized by the FDA on , 2024, for posing elevated risks of initiation, arguing that menthol's cooling sensation and sensory appeal facilitate nicotine uptake among non-smokers. Groups such as the Campaign for Tobacco-Free Kids contend that these authorizations undermine efforts to curb adolescent vaping epidemics, citing National Tobacco Survey data showing menthol e-cigarettes' popularity among users despite NJOY's lower reported trial rates in premarket studies. Critics, including contributors to Respiratory Medicine, have faulted the FDA's risk-benefit analysis for underemphasizing gateway effects, where experimentation with flavored NJOY pods could lead to sustained or transition to cigarettes, though causal evidence for such progression remains debated in peer-reviewed literature. Perceptions of NJOY products' relative have also drawn ; a 2024 study of adult smokers found that only 19% accurately assessed the harms of NJOY 2.0 devices, with many underestimating compared to traditional cigarettes, potentially fostering overconfidence in switching. Advocacy organizations have highlighted NJOY's marketing practices, including point-of-sale displays and online promotions, as insufficiently restricted to prevent exposure, echoing broader concerns about e-cigarette advertising's influence on documented in randomized trials. These criticisms persist despite FDA findings that authorized NJOY tobacco-flavored variants exhibit low appeal, with post-market ongoing to monitor real-world risks. Sources opposing NJOY authorizations, often affiliated with nonprofits, reflect institutional priorities favoring de-nicotinization over , contrasting with regulatory approvals grounded in adult switching data.

Market Impact and Controversies

Achievements and Industry Influence

NJOY achieved a pivotal regulatory milestone in April 2022 when the U.S. (FDA) issued marketing granted orders for the NJOY ACE pod-based device and its 2.4% and 5.0% tobacco-flavored pods, marking the first such authorization for a modern pod system. This approval followed an extensive review of scientific data submitted via Premarket Tobacco Product Application (PMTA), establishing NJOY as a compliant alternative in a market dominated by unauthorized products. Additional FDA decisions in June 2022 authorized select NJOY Daily disposable e-cigarette products in tobacco flavors, further validating NJOY's product portfolio. In June 2024, NJOY secured the FDA's first marketing authorizations for -flavored e-vapor products, encompassing four NJOY ACE Pod variants at 2.4% and 5.0% strengths. These grants were based on evidence that the products assist adult in completely switching from combustible cigarettes, with net benefits derived from reduced exposure to harmful outweighing potential youth initiation risks. As of that date, NJOY ACE remained the sole pod-based system with FDA authorization, and NJOY held the only approved menthol e-vapor options. These regulatory successes have exerted influence on the e-cigarette industry by demonstrating viable pathways for PMTA compliance amid stringent FDA oversight, prompting competitors to invest in similar evidentiary submissions rather than relying on illicit market dominance. NJOY's early innovations, including patents for designs simulating traditional smoking aesthetics (e.g., translucent ash simulators), contributed to product evolution toward user satisfaction mimicking combustible cigarettes. With over 80 patents filed globally—27 granted as of recent records—NJOY has shaped technological standards in vapor delivery systems. Following its 2023 acquisition by Group, NJOY's market positioning strengthened, with approximately 65% of surveyed retailers anticipating enhanced performance and gains due to expanded distribution and resources. This has bolstered NJOY's role in the U.S. vaping sector, where authorized products like NJOY represent a minority (under 15% of sales) against unauthorized disposables, yet exemplify a shift toward regulated alternatives.

Patent Disputes and Competitive Pressures

NJOY has been embroiled in multiple disputes, primarily with Labs, escalating after Altria's acquisition of NJOY in April 2023. In June 2023, Labs filed complaints with the U.S. International Trade Commission () alleging that NJOY's devices infringed four patents related to vaporizer technology, including airflow pathways and formulations. On January 29, 2025, the issued a final determination confirming the infringement, resulting in a ban on U.S. imports and sales of the infringing NJOY products, which NJOY sourced from Chinese manufacturers without licensing 's . In response, NJOY initiated counteractions, filing its own ITC complaint against in August 2023, accusing Juul of infringing two NJOY patents (U.S. Patent Nos. 10,334,881 and 11,497,864) related to e-cigarette pod systems. The ITC terminated NJOY's complaint in March 2025 after finding no violation by Juul, though appeals and parallel litigation persist in U.S. federal courts and the in Europe, where NJOY has challenged nine Juul patents with mixed rulings favoring Juul in most cases as of early 2025. Juul expanded its claims in August 2025, filing additional suits against NJOY's DAILY product for infringing a nicotine-salt issued earlier that year. These disputes have imposed operational constraints on NJOY, forcing discontinuation of the line and reliance on FDA-authorized alternatives amid disruptions from import bans. Beyond patents, NJOY faces competitive pressures from dominant players like and Reynolds American's , which hold larger market shares in authorized closed-system pod devices, as well as unregulated disposable vapes from brands such as Elf Bar that capture significant youth and adult segments despite FDA enforcement. In October 2023, NJOY and filed a seeking to halt imports of popular disposable vapes, citing and regulatory violations, reflecting efforts to counter the illicit market's estimated 11.8% share held by disposables like Geek Bar. The vaping industry's rapid growth, projected to expand from USD 28.17 billion in 2023 to USD 182.84 billion by 2030, intensifies rivalry, with NJOY's post-acquisition strategy hampered by stringent FDA premarket authorizations—NJOY holds four of the limited approvals for disposables as of mid-2025—while competitors navigate similar barriers and black-market alternatives erode pricing power. These pressures underscore NJOY's vulnerability in a where in pod-based systems clashes with protections and regulatory scrutiny favoring established incumbents.

References

  1. [1]
    NJOY Electronic Cigarettes - Company Profile and News
    NJOY Electronic Cigarettes provides electronic cigarette products. The Company offers e-liquid, rechargeable, and traditional tobacco cigarette products.
  2. [2]
    NJOY - Crunchbase Company Profile & Funding
    NJOY is a trading name of NJOY, LLC, an independent American company that manufactures and distributes electronic cigarettes and vaping products.
  3. [3]
  4. [4]
    NJOY - LinkedIn
    Apr 5, 2021 · NJOY is one of the largest independent electronic nicotine device (ENDS) companies in the US and a leader in the revolution against combustible cigarettes.
  5. [5]
    Altria Announces Definitive Agreement to Acquire NJOY Holdings, Inc.
    Mar 6, 2023 · Altria to gain full global ownership of NJOY's e-vapor product portfolio, including NJOY ACE, currently the only pod-based e-vapor product ...
  6. [6]
    Altria invests $2.75 billion in NJOY electronic cigarette startup
    Mar 6, 2023 · The Marlboro maker gets full ownership of NJOY's e-vapor product portfolio, the Virginia company said Monday, including its pod-based e-vapor ...
  7. [7]
    FDA Authorizes Marketing of Four Menthol-Flavored E-Cigarette ...
    Jun 21, 2024 · The FDA issued marketing granted orders to NJOY LLC for four menthol-flavored e-cigarette products – NJOY ACE Pod Menthol 2.4%, NJOY ACE Pod ...<|separator|>
  8. [8]
    FDA Issues Marketing Decisions on NJOY Ace E-Cigarette Products
    Apr 26, 2022 · On April 26, the FDA issued decisions on multiple NJOY Ace e-cigarette products, including the authorization of four new tobacco products.Missing: achievements controversies
  9. [9]
    FDA Issues Marketing Decisions on NJOY Daily E-Cigarette Products
    Jun 10, 2022 · On June 10, the FDA issued decisions on multiple NJOY Daily e-cigarette products, including the authorization of two new tobacco products ...Missing: achievements controversies
  10. [10]
    FDA Decision to Authorize NJOY ACE Menthol Was Based ... - Qeios
    Aug 30, 2024 · FDA Decision to Authorize NJOY ACE Menthol Was Based on a Rigorous Review of the Science to Determine That the Benefits Outweigh the Risk.Missing: achievements | Show results with:achievements
  11. [11]
    FDA Sued Over Years-Long Internal Review of Flavored ENDS MDO
    Aug 26, 2025 · In December 2020, FDA issued a deficiency letter, asserting that the four PMTAs for other-flavored NJOY DAILY failed to demonstrate that such ...Missing: achievements controversies
  12. [12]
    NJOY Sues FDA Over Delays in Flavored E-Cigarette Approval
    Aug 25, 2025 · According to NJOY, the FDA has failed to adhere to statutory deadlines stipulated in the Family Smoking Prevention and Tobacco Control Act. The ...Missing: achievements controversies
  13. [13]
    FDA Belatedly and Arbitrarily Approves Menthol Vapes
    Jun 24, 2024 · The FDA says NJOY presented compelling evidence that smokers are more likely to successfully switch if they can vape menthol-flavored ...
  14. [14]
    Smoke & Mirrors - PHOENIX magazine
    Apr 1, 2014 · So in 2006, Weiss and his brothers Mark and Jeffrey created NJoy. The first NJoy offices housed 10 employees in Scottsdale Airpark. The ...Missing: Sottera early
  15. [15]
    Independent Ecigs manufacturer NJOY declares bankruptcy
    Sep 20, 2016 · NJOY was founded in 2006 as Sottera by Mark Weiss. The company became the largest independent e-cigarette and vaping company in the USA and ...Missing: initial | Show results with:initial
  16. [16]
    NJOY chairman's smokeless success | Business - jewishaz.com
    Apr 8, 2015 · ... Mark to found NJOY in late 2006. The products work by vaporizing what's called an “e-liquid” containing nicotine. The e-cigarette devices ...Missing: early history
  17. [17]
    Has NJOY Resolved the E-Cigarette's Image Problem?
    Apr 26, 2013 · In 1995, an entrepreneur named Pu Danming, operating as general manager of the China Healthy Cigarette Development Company, marketed a “ ...
  18. [18]
    SOTTERA INC NJOY v. FOOD DRUG ADMINISTRATION (2010)
    NJOY has imported and distributed e-cigarettes since 2007. Id. at 2, 4. The liquid nicotine in each e-cigarette is derived from natural tobacco plants, Decl.Missing: inception | Show results with:inception<|control11|><|separator|>
  19. [19]
    Spotlight on: NJOY - Supermarket News
    It has not exactly been a smooth road for the company, founded by the Weiss family in 2006 after Mark Weiss came across a crude e-cigar device. Initially, most ...
  20. [20]
    Sottera v. FDA/Smoking Everywhere v. FDA (2009)
    On April 15, 2009, the FDA denied the import into the U.S. of e-cigarettes and accessories made by two companies called Smoking Everywhere, Inc. and Sottera, ...
  21. [21]
  22. [22]
    NJOY Electronic Cigarettes Receives $20 Million Investment ...
    NJOY Electronic Cigarettes Receives $20 Million Investment. 4/9/2012 ... product pipeline and a strong executive team, NJOY is positioned for significant growth.
  23. [23]
    Cumberland Farms Inks Distribution Deal With NJOY
    Cumberland Farms Inks Distribution Deal With NJOY. NJOY Kings electronic cigarettes now available at chain's nearly 600 locations Dec. 03, 2012.
  24. [24]
    NJOY's New King E-Cig Could Be 'Game-Changer' - CSP Daily News
    Aug 14, 2012 · Scheduled to be released in the fall, NJOY King offers a "master blend" flavor profile, similar size and weight to tobacco cigarettes, and a ...
  25. [25]
    NJOY Introduces Revolutionary Electronic Cigarettes: The NJOY Kings
    Dec 6, 2012 · NJOY offers a variety of rechargeable and non-rechargeable electronic cigarette products made for adult smokers. These products provide nicotine ...<|separator|>
  26. [26]
    NJOY Officially Launches Kings - CSP Daily News
    Dec 7, 2012 · "This product is unlike any other e-cigarette on the market today offering the very first truly satisfying alternative to the tobacco cigarette.
  27. [27]
    NJOY Vapes - Tobacco Insider
    Sep 11, 2025 · ​NJOY is founded in 2007 as one of the first vape companies in the U.S. and had a turbulent ride before becoming a wholly owned subsidary of ...
  28. [28]
    New NJOY Products Will 'Bring Vape National': Herzog
    May 14, 2014 · NJOY has announced that it is refreshing and expanding its product line by introducing a rechargeable line of e-cigarettes and a "high-vapor" product or vapor- ...Missing: 2011-2015 | Show results with:2011-2015<|separator|>
  29. [29]
    [PDF] E-Cigarette Market Trends in Traditional U.S. Retail Channels, 2012 ...
    Jan 15, 2015 · In the case of NJOY and Logic, most of their growth was attributable to shifts in unit sizes. “One count” products constituted 65.1% of NJOY.
  30. [30]
    E-Cigarette Maker NJOY Seen as Takeover Target Amid Innovation
    Dec 5, 2012 · A single NJOY King sells for $7.99 and lasts as long as two packs of cigarettes, the company said. It is the same length and diameter as a ...
  31. [31]
    E-Cigarettes, “Vapes” and Other Electronic Nicotine Delivery ... - FDA
    Sep 17, 2025 · E-Cigarettes, “Vapes” and Other Electronic Nicotine Delivery Systems (ENDS) Authorized by the FDA ; NJOY ACE Device, NJOY ACE POD Menthol 5%.
  32. [32]
    NJOY ACE Device Kit - Electric Tobacconist USA
    Sleek & ergonomic design · Easy-to-use magnetic pod system · Compatible with NJOY ACE PODS (sold separately) · Rechargeable battery.Missing: launch | Show results with:launch
  33. [33]
  34. [34]
    NJOY Ace Review: 2 Years Later - Vaping360
    Nov 24, 2021 · The NJOY Ace is prefilled pod vape with a sophisticated look. It's stealthy, but compact and solid. It's a one-step device. Drop in a pod. Vape when ready.
  35. [35]
    NJOY Daily - The Vapor Shoppe
    Simply inhale to activate the NJOY Daily e-cigarette. No buttons or charging required. Enjoy a smooth and flavorful vaping experience with each puff.
  36. [36]
    NJOY | ACE, Pods & Disposables - Electric Tobacconist USA
    NJOY DAILY disposable e-cigarettes are available in Rich Tobacco and Menthol flavors. The flavors are available in 4.5% nicotine by weight (45mg/g) and 6% ...DAILY Menthol · NJOY Pods · NJOY DAILY Rich Tobacco · NJOYACE Device
  37. [37]
    Contact Us - NJOY
    How can we help? · Where can I purchase NJOY® products? NJOY® products are available at select retail locations nationwide and through select online retailers.
  38. [38]
    [PDF] Technical Project Lead (TPL) Review of PMTAs - FDA
    Jun 9, 2022 · o. The new product e-liquids contain nicotine salt formulations, which may be easier (i.e., less irritating) to inhale at high nicotine ...
  39. [39]
    Physical and Chemical Characterization of Aerosols Produced from ...
    Dec 9, 2024 · The NJOY Daily ERT 6% e-liquid and the open e-liquids APT 3.5% and APT 5% contained 50:50 PG:VG.<|control11|><|separator|>
  40. [40]
    NJOY Receives First FDA Authorizations for Menthol E-Vapor Products
    Jun 21, 2024 · The US Food and Drug Administration (FDA) issued marketing orders for NJOY ACE Pod Menthol 2.4%, NJOY ACE Pod Menthol 5%, NJOY DAILY Menthol 4.5%, and NJOY ...
  41. [41]
    NJOY Daily Is the First FDA-Authorized Disposable - Vaping360
    Jun 10, 2022 · The FDA has authorized sale of the NJOY Daily e-cigarette in two tobacco flavors—-the first disposable vaping product okayed by the agency.
  42. [42]
    NJOY Submits Premarket Tobacco Product Applications to the FDA ...
    May 20, 2024 · On April 26, 2022, the FDA authorized the NJOY ACE device and NJOY ACE Classic Tobacco (2.4% and 5%) and Rich Tobacco (5%) pods as APPH. The FDA ...Missing: launch | Show results with:launch
  43. [43]
    Juul's Bid to Block New NJoy Daily and Ace Vapes Gets ITC Review
    Sep 10, 2025 · Juul is seeking to block imports of NJoy's Daily disposable e-cigarettes and a redesigned version of the rechargeable Ace pod system, which it ...
  44. [44]
    Say Goodbye to the NJOY Ace - For Now Anyway - Vaping360
    Apr 7, 2025 · New Product Releases [September 2025]. Latest vaping products and nicotine pouches from September 2025. Mon Oct 6 2025. ByVaping360 Staff.Missing: King | Show results with:King
  45. [45]
    Premarket Tobacco Product Applications - FDA
    Mar 28, 2024 · A premarket tobacco product application (PMTA) can be submitted by any person for any new tobacco product seeking an FDA marketing order.Missing: NJOY | Show results with:NJOY
  46. [46]
    FDA Sued Over Years-Long Internal Review of Flavored ENDS MDO
    Aug 27, 2025 · In March 2020, NJOY submitted premarket tobacco product applications (PMTAs) for eight variations of its NJOY DAILY line of disposable ENDS ...Missing: interactions | Show results with:interactions
  47. [47]
    Decisions of the FDA on premarket tobacco product applications - NIH
    Mar 13, 2024 · The PMTA review process comprises four phases: 1) acceptance review, 2) filing review, 3) application review and action, and 4) postmarket ...Missing: history timeline
  48. [48]
    Premarket Tobacco Product Marketing Granted Orders - FDA
    2022 Premarket Tobacco Product Marketing Granted Orders ; NJOY LLC, NJOY DAILY EXTRA Rich Tobacco 6%, ENDS, 06/10/2022, PM0000631 ; R.J. Reynolds Vapor Company ...Missing: history timeline
  49. [49]
    FDA Defies Public Health by Authorizing Menthol E-cigarettes for Sale
    Jun 21, 2024 · The Food and Drug Administration (FDA) dealt a blow to public health by authorizing the sale of four menthol e-cigarettes manufactured by NJOY LLC.
  50. [50]
    Fed Up with the FDA, Big Tobacco Goes Nuclear - Vaping360
    Aug 26, 2025 · Altria Group vape subsidiary NJOY has filed a federal lawsuit alleging the FDA has violated the Tobacco Control Act by delaying marketing ...Missing: achievements | Show results with:achievements
  51. [51]
    JUUL LABS FILES ADDITIONAL PATENT INFRINGEMENT ...
    August 8, 2025. Juul Labs filed complaints today against NJOY and Altria with the United States International Trade Commission (ITC) and the United States ...Missing: ongoing | Show results with:ongoing
  52. [52]
    US to halt imports, sale of Njoy Ace products - C-Store Dive
    Jan 31, 2025 · The US International Trade Commission ruled on Wednesday that some Njoy Ace vaping products violated patents held by rival vaping company Juul.Missing: litigation | Show results with:litigation
  53. [53]
    Altria Pulls NJOY Ace from US Market After ITC Patent Ruling
    Apr 21, 2025 · Altria Group has halted the sale of its NJOY Ace e-cigarette products in the United States, effective March 31, 2025, after the US International Trade ...Missing: ongoing | Show results with:ongoing<|separator|>
  54. [54]
    Half-time in the e-cigarette battle between NJOY and Juul Labs
    Nov 29, 2024 · Paris central division upholds key Juul Labs patent and dismisses NJoy's revocation action in fourth e-cigarette judgment this month.Missing: ongoing | Show results with:ongoing
  55. [55]
    NJOY Brings Sweeping Litigation Against Illicit Disposable Vapor ...
    Oct 19, 2023 · The suit alleges that these companies manufacture, distribute, market and sell products that violate California's flavor ban law, are unlawful ...
  56. [56]
    NJOY LLC v. IMIRACLE HK LTD (2024) - FindLaw Caselaw
    NJOY initiated the litigation on February 28, 2024, asserting claims under California's Unfair Competition Law (“UCL”), Cal. Bus. & Prof. Code § 17200 et ...Missing: ongoing | Show results with:ongoing
  57. [57]
    NJOY vs. Elf Bar: Inside the Lawsuit Banning Flavored Vapes in CA
    Oct 18, 2025 · The court acknowledged NJOY's argument that by circumventing costly regulatory compliance, the defendants gained an unfair advantage that ...
  58. [58]
    In re NJOY, Inc. Consumer Class Action Litigation
    Plaintiffs allege first that NJOY's failure to include certain harmful ingredients on the label of NJOY e-cigarettes -- namely, [propylene] glycol and glycerin ...
  59. [59]
    Update on Altria's Pending Acquisition of NJOY Holdings, Inc.
    May 26, 2023 · Altria Group, Inc. (NYSE:MO) announces that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, ...
  60. [60]
    Altria Completes Acquisition of NJOY Holdings, Inc.; Updates 2023 ...
    Jun 1, 2023 · Altria completed the acquisition of NJOY, funded by $2.75B, and expects 2023 adjusted EPS of $4.89-$5.03, with NJOY e-vapor products marketed ...
  61. [61]
    Njoy Leadership Changes Following Altria Acquisition
    Jun 1, 2023 · Njoy has a new president and CEO, Altria announced Thursday after completing its acquisition of the e-vapor company.Missing: post- developments
  62. [62]
    provides 2024 full-year earnings guidance - SEC.gov
    Feb 1, 2024 · (NJOY Transaction). Our teams executed NJOY's business plans with speed and focus after the completion of the NJOY Transaction. Our efforts ...Missing: post | Show results with:post
  63. [63]
    Altria: Executing Beautifully On Its NJOY Acquisition - Seeking Alpha
    Aug 21, 2024 · The NJOY acquisition has shown promise, with significant growth in shipment volume and market share, offsetting the decline in smokeable ...
  64. [64]
    Altria Completes $2.75B NJOY Acquisition - Convenience Store News
    Jun 1, 2023 · The manufacturer entered into a definitive agreement to acquire NJOY Holdings Inc. for approximately $2.75 billion in cash on March 6.
  65. [65]
    NJOY Continues To Drive Altria Group's (MO) Sustained Growth
    Nov 22, 2024 · The company's NJOY shipments grew by 15%, proving the acquisition last year was a great strategic move.
  66. [66]
    NJOY, E-Cigarette Maker, Receives Funding Valuing It at $1 Billion
    Feb 28, 2014 · His brother Mark, also a lawyer, founded NJOY in 2006 after a trip to China inspired him to enter the electronic cigarette market. During his ...
  67. [67]
    Mark Weiss - Attorney at Weiss & Moy, P.C. - LinkedIn
    Founder. NJOY (Sottera, Inc). Sep 2006 - Oct 2016 10 years 2 months. Scottsdale, Arizona. The Company sells its product under the trademark NJOY (www.njoy.com) ...
  68. [68]
    Craig Weiss, Co-Founder Of NJOY - NPR
    Nov 22, 2013 · Jessica Harris speaks with Craig Weiss, co-founder of NJOY, an electronic cigarette company that sells the NJOY King.Missing: founders | Show results with:founders
  69. [69]
    NJOY's Journey: From $1B Val t… - Seed to Harvest - Apple Podcasts
    Apr 10, 2025 · Our first episode features Mark Weiss and Jeff Weiss, the founders of NJOY, a billion-dollar e-cigarette company. They dive into the ...Missing: Sottera history 2006
  70. [70]
    The E-Cigarette Industry, Waiting to Exhale - The New York Times
    Oct 26, 2013 · NJOY was started by Mr. Weiss's brother, Mark Weiss, a lawyer in Scottsdale, who was inspired by a crude version of an electronic cigar at a ...
  71. [71]
    NJOY | Home
    NJOY was founded in 2006 and on June 1, 2023, NJOY became a wholly-owned subsidiary of Altria Group, Inc. NJOY's founding mission was to provide adult smokers ...Missing: 2006-2010 | Show results with:2006-2010
  72. [72]
    NJOY Receives First FDA Authorizations for Menthol E-Vapor Products
    Jun 21, 2024 · In May 2024, NJOY submitted a supplemental PMTA to the FDA to commercialize and market the NJOY ACE 2.0 device. This device incorporates access ...
  73. [73]
    NJOY LLC | BBB Business Profile | Better Business Bureau
    Business Management: Mr. Mike Unangst, SVP Operations & Trade Marketing: Mr. Jeffrey Weiss, General Counsel. Additional Contact Information.
  74. [74]
    NJOY CEO and Key Executive Team - Craft.co
    NJOY's CEO is Ryan Nivakoff. Key executives include David Graham (Chief Impact Officer), Linda Valentine (VP Regulatory CMC), and Priscilla Tan (EVP, Revenue).Missing: current | Show results with:current
  75. [75]
    Electronic cigarettes for smoking cessation - Lindson, N - 2024
    Jan 8, 2024 · Nicotine e‐cigarettes can help people to stop smoking for at least six months. Evidence shows they work better than nicotine replacement therapy ...
  76. [76]
    Electronic cigarettes for smoking cessation - PubMed
    Jan 8, 2024 · There is high-certainty evidence that ECs with nicotine increase quit rates compared to NRT and moderate-certainty evidence that they increase quit rates ...
  77. [77]
    A Randomized Trial of E-Cigarettes versus Nicotine-Replacement ...
    Jan 30, 2019 · This resulted in a 1-year abstinence rate of 17.7% in the e-cigarette group, as compared with 8.0% in the nicotine-replacement group (relative ...
  78. [78]
    Efficacy and Safety of E-Cigarette Use for Smoking Cessation
    Conclusions: Among individuals attempting to quit smoking, nicotine e-cigarettes are more efficacious than conventional nicotine replacement or behavioral ...
  79. [79]
    Efficacy of Electronic Cigarettes vs Varenicline and Nicotine ...
    Jan 29, 2024 · In this randomized clinical trial, ECs were as effective in helping smokers quit as varenicline and more effective than nicotine chewing gum ...
  80. [80]
    Efficacy and Safety of E-Cigarette Use for Smoking Cessation
    May 4, 2023 · We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs), identified through a systematic search of the MEDLINE, EMBASE, and ...
  81. [81]
    Electronic cigarette use and smoking cessation in cohort studies and ...
    Oct 13, 2021 · The aim of this systematic review and meta-analysis was to assess the association between e-cigarette use and subsequent smoking cessation in cohort studies.Missing: efficacy | Show results with:efficacy
  82. [82]
    Clinical Outcomes of a Nationwide, Naturalistic E-Cig Trial ...
    The purpose of this study is to measure changes in smoking behavior during and following sampling of an e-cigarette product. E-cigarettes are classified by the ...<|control11|><|separator|>
  83. [83]
    Electronic cigarettes: not evidence-based cessation - PMC - NIH
    To date, two randomized controlled trials have shown that e-cigarettes are not effective smoking-cessation tools.
  84. [84]
    Health Effects of Vaping | Smoking and Tobacco Use - CDC
    Jan 31, 2025 · Other potential harms of e-cigarettes · Nicotine, a highly addictive chemical that can harm adolescent brain development · Cancer-causing ...Missing: NJOY | Show results with:NJOY
  85. [85]
    5 Vaping Facts You Need to Know | Johns Hopkins Medicine
    Research suggests vaping is bad for your heart and lungs. Nicotine is the primary agent in regular cigarettes and e-cigarettes, and it is highly addictive.Missing: NJOY | Show results with:NJOY
  86. [86]
    Immunological and toxicological risk assessment of e-cigarettes
    Based on recent evidence, prolonged exposure to some constituents of e-cig aerosols might result in respiratory complications such as asthma, chronic ...<|control11|><|separator|>
  87. [87]
    E-Cigarettes and Associated Health Risks: An Update on Cancer ...
    There is evidence that e-cigarettes promote lung metastasis of human breast cancer cells. This is an important contribution to understanding the potential risks ...
  88. [88]
    FDA Authorization of Menthol-Flavored E-Cigarettes Is Troubling ...
    Jun 21, 2024 · The FDA's decision today to authorize the sale of four menthol-flavored e-cigarettes made by NJOY – the first time the agency has authorized the sale of any ...Missing: controversies | Show results with:controversies
  89. [89]
    US FDA authorises Juul e-cigarette marketing, imperilling youth ...
    Aug 5, 2025 · Then, last year, the FDA abruptly authorised marketing of NJOY menthol e-cigarette products—the first non-tobacco flavoured vaping products ...<|separator|>
  90. [90]
    [PDF] Risk perceptions and misperceptions of NJOY ACE® 2.0 BLE ENDS ...
    Sep 8, 2024 · Indeed, only 19% of AS in this study had accurate perceptions of harm for NJOY ACE 2.0.
  91. [91]
    E-Cigarette Marketing Exposure is Associated with E-cigarette Use ...
    Marketing restrictions to protect youth include banning advertisements likely to appeal to minors and those using people appearing to be under 25 years of age ...Missing: controversies | Show results with:controversies
  92. [92]
    A Closer Look at the FDA's Authorization of Four Menthol E-Cigarettes
    Jul 1, 2024 · The FDA has now authorized four new e-cigarettes, all of which are menthol flavored. On June 21, 2024, the FDA issued a press release.
  93. [93]
    FDA Greenlights First Menthol E-Cigarettes - Respiratory Therapy
    Jun 21, 2024 · The FDA issued marketing granted orders to NJOY LLC for four menthol-flavored e-cigarette products: NJOY ACE Pod Menthol 2.4%, NJOY ACE Pod ...<|separator|>
  94. [94]
    Patents Assigned to NJOY, Inc. - Justia Patents Search
    The electronic cigarette may also have a translucent ash simulator to further simulate the natural burn of a traditional tobacco cigarette during inhalation.Missing: innovations | Show results with:innovations
  95. [95]
    NJOY Patents - Key Insights and Stats
    NJOY has a total of 84 patents globally, out of which 27 have been granted. Of these 84 patents, more than 48% patents are active.<|control11|><|separator|>
  96. [96]
    Retailers expect a boost for NJOY under Altria - C-Store Dive
    Jul 27, 2023 · About 65% of retailers expect NJOY vaping devices to “perform better and gain market share” under ownership of tobacco giant Altria, according ...
  97. [97]
    Disposable Vapes Eating Into Cigarette Sales, Industry Data Show
    Aug 14, 2024 · Altria's second-quarter report also pointed to growing vape-market share for NJOY. In 2022, before its 2023 acquisition by Altria, NJOY ...
  98. [98]
    U.S. INTERNATIONAL TRADE COMMISSION PROTECTS JUUL ...
    Jan 29, 2025 · NJOY obtained this infringing product from a Chinese manufacturer without ever securing any permissions or licenses from Juul Labs, a problem ...
  99. [99]
    Ace Patent Situation - NJOY
    You may have seen the recently issued cease and desist order prohibiting the importation, distribution and marketing of NJOY Ace® and Pods starting on March 31, ...Missing: Twist | Show results with:Twist
  100. [100]
    Juul wins order banning US imports of Altria vaping devices - Reuters
    Jan 29, 2025 · The U.S. International Trade Commission found that NJOY's ACE devices violated Juul's patent rights in vaporizer innovations. As a result, an ...
  101. [101]
    Patents Wars - Tobacco Insider
    Aug 26, 2025 · NJOY alleges that Juul infringes US Patent No. 10,334,881 and US Patent No. 11,497,864. ITC investigations typically take 15-18 months, faster ...
  102. [102]
    Altria and NJOY Respond to ITC Initial Determination in Complaint ...
    Aug 27, 2024 · In August 2023, NJOY filed a similar, independent patent infringement complaint against JUUL with the ITC seeking a ban on the importation ...<|separator|>
  103. [103]
    Trade Commission Ends Altria's Patent Infringement Case Against ...
    Mar 14, 2025 · In 2023, Juul Labs filed complaints against Njoy alleging its Njoy Ace e-cigarette device infringes on several patents of Juul Labs. Altria ...
  104. [104]
    Juul Labs ahead in battle with NJOY but fight continues at Court of ...
    NJOY wants the Unified Patent Court to remove nine patents protecting Juul Labs' vaporizer technology from the market. For this reason, the ...
  105. [105]
    Juul Seeks Ban on New NJoy Daily, Ace Vapes on Patent Claims (1)
    Aug 11, 2025 · The NJoy Daily and a redesigned version of the Ace use nicotine-salt formulations to deliver cigarette-like “satisfaction,” infringing Juul's US ...
  106. [106]
    Juul's momentum slips as NJOY woos customers with dollar e ...
    Aug 20, 2019 · E-cigarette giant Juul's momentum is slowing. Rival NJOY is gaining market share with promotions like 99-cent e-cigarettes. Vuse and blu are ...Missing: industry | Show results with:industry
  107. [107]
    NJOY/Altria Asks Court to Stop Sales of Popular Disposable Vapes
    Oct 19, 2023 · Altria Group vape subsidiary NJOY has filed a federal lawsuit, asking the court to stop the import and sale of popular disposable vapes.
  108. [108]
  109. [109]
    E-cigarette And Vape Market Size And Share Report, 2030
    The global e-cigarette and vape market size was estimated at USD 28.17 billion in 2023 and is projected to reach USD 182.84 billion by 2030, growing at a CAGR ...
  110. [110]
    Vaping, Panic, and Prohibition: Why the UC-Davis Study Needs ...
    Jul 14, 2025 · To date, the FDA has approved only four disposable pod vapes, all of which are NJOY brand devices made by a division of Altria Corporation. ... As ...
  111. [111]
    US E-Cigarette Market Size, Trends, Share, Forecast by 2033
    The United States e-cigarette industry is very competitive due to numerous giant players and new entrants competing for the clients' attention. The current ...<|separator|>